Preliminary studies of EDDA-tricine-HYNIC-Tyr³-octreotide labelled with technetium-99m: radiopharmaceutical development for the diagnosis of neuroendocrine tumours. (19th January 2010)

• Record Type: Journal Article
• Authors: Melero, Laura Terumi Ueda Hernandes; Muramoto, Emiko; De Araujo, Elaine Bortoleti
• Is Part Of: Atoms for peace. Volume 3:Number 1(2010)
• Page Start: 56
• Page End: 64
• Publication Date: 2010-01-19
• Subjects: octreotide -- somatostatin -- technetium-99m -- neuroendocrine tumours -- tumour diagnosis -- Swiss mice -- radiochemicals -- blood clearance -- labelled peptides -- kidney uptake -- urinary excretion; Nuclear energy -- Periodicals; Nuclear energy -- Management -- Periodicals; 333.792405
• Languages: English
• ISSNs: 1741-640X

Abstract

The use of labelled molecules with high specificity for an organ or receptor in scintigraphy generates good local images and minimises the exposure of other organs. Octreotide was the first somatostatin synthetic analogue introduced in clinical use in the localisation of tumours with superexpression of somatostatin receptor (sstr). This work studied the labelling of HYNIC-Tyr3-octreotide with 99mTc and the biodistribution of labelled compounds in normal Swiss mice. A high radiochemical yield was obtained when using 20 μg of HYNIC-TOC, 10 mg of EDDA, 20 mg of tricine, 15 μg of SnCl2.2H2O, pH 7.5 and 10 min of boiling water bath. Biodistribution studies showed fast blood clearance of the labelled peptide with high kidney uptake and urinary excretion. The low background in the abdominal region is favourable for the diagnosis of neuroendocrine tumours.